Trials / Completed
CompletedNCT00820079
ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study to Investigate the Efficacy, Mechanism of Action, Pharmacokinetics, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 as Monotherapy in Patients With Gastroesophageal Reflux Disease (GERD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Addex Pharma S.A. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal reflux.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADX10059 | oral administration |
| DRUG | ADX10059 Matching Placebo | oral administration |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-10-01
- First posted
- 2009-01-09
- Last updated
- 2009-12-24
Locations
11 sites across 4 countries: Austria, Belgium, France, Germany
Source: ClinicalTrials.gov record NCT00820079. Inclusion in this directory is not an endorsement.